![European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug](https://www.ecco-ibd.eu/images/6_Publication/6_4_Congress_abstract_search/abstracts2020/op21-f0001.jpg)
European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug
![Children | Free Full-Text | Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review | HTML Children | Free Full-Text | Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review | HTML](https://www.mdpi.com/children/children-09-00617/article_deploy/html/images/children-09-00617-g001.png)
Children | Free Full-Text | Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review | HTML
![European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC21/abstracts/0000000270/0000626130/Images/ChangesinADAlevels.jpg)
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra
![Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/62abfb1a-aa3a-4542-a03d-8157bed26510/gr1.jpg)
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology
![European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC21/abstracts/0000000270/0000626130/Images/ChangesinCFlevels.jpg)
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
![First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrgastro.2013.31/MediaObjects/41575_2013_Article_BFnrgastro201331_Fig1_HTML.jpg)
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical M
![PDF) DOP064 ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease PDF) DOP064 ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease](https://i1.rgstatic.net/publication/322889934_DOP064_ECCO_expert_consensus_and_topical_review_on_treatment_exit_strategies_in_inflammatory_bowel_disease/links/5f28f12fa6fdcccc43a89da1/largepreview.png)
PDF) DOP064 ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
![European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC21/abstracts/0000000270/0000648040/Images/figure2202103102136148581.png)
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
![PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment](https://i1.rgstatic.net/publication/352704305_Biologics_recommendations_in_the_ECCO_guidelines_on_therapeutics_in_Crohn's_disease_Medical_treatment/links/60d9c15392851ca9449080ce/largepreview.png)
PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment
![Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4b41a50f-4360-4527-bf89-ebbababb4027/fx1_lrg.jpg)
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology
![Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia](https://www.irjournal.org/upload//thumbnails/ir-2019-00026f2.jpg)
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
![Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4676ad7f-c189-43bf-9107-8362d2fe85ed/gr1.jpg)
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
![Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition) Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition)](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2444382416000572:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNcRcp7AE8pxI7/lU7i5mKGl6o67DY/uL2+/IxZemV5MIi07vCLoCcvKXXujOVEhV9vDm6Xx1nEwb6Qeq+6rTkxm7zZ9W2YuN2pwm22U3BrRBdF6iXjnaiYRV1bxIIoF2fjElgbNsuJc9dYWDftPOkQHfiC4C5xjSNtOZ7+KLf2IuStQuyHdwkNp0EfvM41YH5BcvE27A8x16LJoy0jdZfM9DNcSpuP3AXVP0XhZNUsxS3gA19e+oEkYD8wxGNjbnSw=)
Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition)
![Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis - Yao - 2021 - Journal of Gastroenterology and Hepatology - Wiley Online Library Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis - Yao - 2021 - Journal of Gastroenterology and Hepatology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/f8163656-791e-4070-8261-e3804ed56bba/jgh15373-fig-0001-m.jpg)
Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis - Yao - 2021 - Journal of Gastroenterology and Hepatology - Wiley Online Library
![Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/9a28501a-1f92-4d2c-8ac6-e3a132b0e993/fx1.jpg)
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
![PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0a8e924d287b22861a1cb440f147aa0618dbc982/2-Table1-1.png)
PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar
![European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC21/abstracts/0000000270/0000648040/Images/figure3202103102136113746.png)
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
![European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC21/abstracts/0000000270/0000648040/Images/figure1202103102137169320.png)